The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.
In conjunction with the strategic evolution, the Company appointed Jian Irish, Ph.D., M.B.A., as Chief Executive Officer. Based on a revised capital allocation strategy, the Company extended its ...
Find how Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by Sequencing Base Editors ...
Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...
In a few decades, gene-editing technologies could reduce the likelihood of common human diseases. Societies must use this time to prepare for their arrival. Read the paper: Heritable polygenic editing ...
Researchers restored hearing in preclinical mouse models with a specific form of inherited deafness called DFNA50 caused by mutations in microRNA, by using a novel in vivo CRISPR genome editing ...
Technologies at the Advanced Rodent Transgenics Laboratory include genome editing design and implementation and transgenic ...
Back in 2016, a group of researchers led by Harvard’s David Liu, PhD, published a paper in Nature that reported the development of base editing. Base editing, they wrote, is “a new approach to genome ...
Restricted access to genome-editing technologies poses serious challenges for countries like India that urgently need such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback